Alkem Laboratories FY26: Record Profits, Semaglutide Sprint, Occlutech Bet

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1. At a Glance

Alkem closed FY26 with its highest annual net profit on record—₹2,302 crore, up 6.3% from ₹2,165 crore in FY25. Revenue climbed 13.5% to ₹14,712 crore. EBITDA crossed ₹3,000 crore for the first time, with margin expanding from 19.4% to 20.4%.

The domestic branded generics business grew 9.7%, slower than headline revenue, because of a transitional restructuring in trade generics (the lower-margin channel). Internationally, the business grew 22.5%, held back by the crore-heavy decision to bet EUR 99 million (~₹1,100 crore) on Occlutech, a Swiss heart-device maker. A semaglutide launch in March 2026 claimed 11% market share within weeks.

The tension: margin has finally broken north, the chronic therapy mix is shifting upward, but the company has just committed a year’s operating cash flow to a non-pharma acquisition while defending against tax scrutiny and positioning for leadership transition.

The question: does a 21.2% ROCE justify a 26.4x P/E when the company is no longer purely pharmaceutical?

2. Introduction

Alkem is the fifth-largest pharmaceutical company in India by market share (4.1% as of 9M FY25), with the #1 position in anti-infectives and top-3 spots in GI, pain, and vitamins/minerals/nutrients. It has 17 brands exceeding ₹1 billion in annual sales, including three “mega brands” above ₹5 billion. The distribution network spans 12,500+ field force, 9 central warehouses, 75+ depots, and 8,400+ stockists—the second-largest network in the country.

In February 2026, Alkem announced a binding offer to acquire 51–55% of Occlutech Holding AG, a Switzerland-based structural heart device company, for EUR 180.7 million (valued at ~₹1,952 crore equity). The transaction is expected to close within 45–60 days from the concall (early June 2026), funded entirely from cash on hand.

In March 2026, CEO Dr. Vikas Gupta resigned; his tenure closes on 30 June 2026 to allow a transition. The board is conducting a search using “top 3 global head-hunters.”

On 2 June 2026, Alkem launched semaglutide pre-filled syringes in a single-shot weekly format at ₹350 after DCGI approval, priced 80% below the innovator. Within weeks, market share in the GLP-1 segment climbed to 11% unit share per IQVIA, positioning it as a material growth vector for FY27.

3. Business Model: WTF Do They Even Do?

Alkem manufactures and sells branded and generic pharmaceuticals domestically, exports generics and biosimilars internationally, and operates contract manufacturing for biologics. The three segments are domestic (70% of revenue), international (30%), and emerging non-pharma (Occlutech, Enzene, MedTech—currently immaterial).

Domestic: Acute Dominance, Chronic Acceleration

The domestic business derives over 80% of revenue from acute therapies: anti-infectives (rank 1), pain (rank 3), and GI (rank 3). These categories are slower-growing and price-controlled. Chronic therapies—anti-diabetes, cardiology, neurology, respiratory, dermatology—now contribute close to 22% of branded generics, up 1% annually over four years.

Semaglutide enters this chronic ramp as a high-ticket new product. Management flagged it as “one of the biggest priorities” for FY27. The launch reached 11% market share in unit sales within three weeks, suggesting either effective market access or meaningful unmet demand or both.

The trade generics channel (below-brand generics sold through drugstore chains) contributed softer growth at 4.3% in FY26, a deliberate de-prioritization to lock down receivables and margin. This carveout as a separate entity means the reported number masks underlying profitability.

International: Generic Focus, Biosimilar Constraints

The company operates in 80 countries with 10+ out-licensing agreements for 7 biosimilars (denosumab, romosozumab and others). The US remains the largest international market, driven by 154 approved ANDAs out of 179 filed. Growth in high-single-digits is structural—new launches offset “value erosion” on existing products, a euphemism for pricing pressure and patent cliffs.

Denosumab (a Prolia/Xgeva biosimilar) approval is progressing in the US, potentially by Q1 FY27, but the company flagged it has “no basket yet,” meaning limited market access. Europe has a “partner” only for one indication, implying other markets await out-licensing. This constraint—a narrow portfolio and dependence on partners—limits upside velocity.

Enzene (US CDMO): Ramp Loss-Making

Enzene Biosciences, Alkem’s biologics/CDMO subsidiary, is profitable in India (“teens EBITDA”) but loss-making in the US during ramp. Management expects US breakeven “maybe this year” but cautioned against extrapolating tariff headlines into immediate scaling—customer cycles are long, and large companies are still setting up in-house capacity.

US CDMO revenue last year was “less than ₹100 crore”; management targets “meaningfully ₹200–300 crore,” but this will take “a couple of years.”

Occlutech (New MedTech): Post-Close Integration

Occlutech, CY25 revenue ₹487 crore, specializes in advanced structural heart devices. The company is profitable and has FDA clearance. Alkem’s bet is geographic: Occlutech’s distribution network in Europe and semi-regulated markets can be leveraged by Alkem’s domestic field force once acquired.

Management described this as “one of our biggest investments in the last 10 years” and paused further M&A for at least 12 months to focus on integration.

4. Financials Overview

Figures are consolidated, in ₹ crore. Result Type: Yearly. Latest period: Mar 2026.

Q4 FY26 Quarterly Details (per management concall, 1 Jun 2026):

Revenue from operations: ₹3,603 crore (+14.6% YoY). EBITDA ₹517 crore, but margin compressed to 14.4% (vs. 12.4% prior year) due to non-recurring charges: ₹602.7 crore gratuity/leave encashment liability from “central loans under labour codes” and ₹747 crore real estate impairment.

Adjusted for these items, Q4 operating profit would sit higher. The concall clarified FY26 EBITDA margin was 20.4% vs. FY25’s 19.4%, and management attributed the expansion to “improving business mix, operating leverage, and continued cost discipline.”

Concall Guidance (Directional, Not Formal)

India: continue 100–150 bps above IPM growth (IPM grew ~10% in FY26; Alkem +11.1%). US (pharma): “high single-digit” growth. RoW: “higher teens” growth. R&D: expected to remain 4–5% of revenue (FY26: 4.2%, Q4 elevated at 6.4% due to filings).

5. Valuation Discussion: Fair Value Range (Educational Only)

What follows is a walkthrough of how three valuation methods work, using this company’s numbers as the example — not a target, not a forecast, not advice.

Method 1: P/E

Annualised EPS (FY26 full year): ₹192.51. Peer band for large-cap Indian pharma: 20–35x. Method 1 outputs: 192.51 × 20–35x = ₹3,850–₹6,738 per share.

Method 2: EV/EBITDA

FY26 EBITDA: ₹3,005 crore. Net cash (cash less borrowings): ₹1,733 − ₹2,047 = negative ₹314 crore (the company carries net debt). Enterprise value for large-cap pharma: 12–18x EBITDA. At 12–18x, EV ranges ₹36,060–₹54,090 crore. Less net debt of ₹314 crore, equity value: ₹35,746–₹53,776 crore, or ₹2,990–₹4,493 per share (on 12 crore shares).

Method 3: Simplified DCF (5-Yr Growth, Terminal Margin)

Assume 12% annual revenue growth (mid-point of historical and concall guidance), 21% EBITDA margin (company target), terminal growth 3%, WACC 9%. This methodology over 5 years and perpetuity yields a per-share range of ₹3,200–₹4,800.

These figures show how the methods work and are not a valuation, a target, or advice.

6. What’s Cooking

Semaglutide GLP-1: Execution in Motion

Launch in March 2026 at ₹350 per injection (pre-filled syringe). By late May 2026, the company had captured 11% unit market share. This is material—GLP-1 market in India is nascent but expanding rapidly (semaglutide, tirzepatide, liraglutide). The company positioned it as a “day 1 launch” and “one of the biggest priorities” for FY27, signalling planned aggressive field-force and KOL expansion.

Occlutech Acquisition: ₹1,100 Crore Cash Outlay, 45–60 Day Close

Binding offer signed February 2026. Expected completion by June/July 2026 (within 45–60 days of the concall). Financial consolidation likely from Q2 FY27. Alkem will hold 51–55% equity. This is the capital event of the year—Alkem now enters high-margin medical devices, a business with different working capital and distribution dynamics.

US Tolvaptan Launch: H2 FY27

Tolvaptan (an aquaretic for hyponatremia/SIADH) approved; expected launch September/October 2026. Market is “limited player, not as crowded” as many US launches, but management cautioned base US business faces “value erosion” over time, so launches offset rather than drive growth.

Ujjain Greenfield Plant: ₹1,036 Crore Phased Investment

In April 2026, the board approved increasing investment in a new formulations facility in Ujjain, Madhya Pradesh, to up to ₹1,036 crore. This follows an 18 March land allotment of ~30 acres. The facility will augment domestic production capacity and is part of the capex pipeline (company guided ₹700–750 crore capex in FY27, now rising post-Occlutech).

Denosumab Biosimilar: Timing Risk

US approval potentially by Q1 FY27, but commercial constraints: the company has no payer “basket” (formulary access), and Europe has a partner only for one indication. This implies out-licensing or delayed launches in other markets. Meaningful contribution will take 12+ months post-approval.

Biosimilar Portfolio Constraints

Management explicitly stated: “we do not have [romosozumab] in our pipeline.” Denosumab faces “pricing pressures for everyone” and constrained geographic footprint. Biosimilar revenue contribution, while growing, remains a small % of total—the company is not a biosimilar powerhouse.

FDA Form 483 & Tax Demand Noise

In May 2026, the US FDA inspected the Daman facility (20 April to 1 May 2026), issuing a Form 483 with seven observations (no data-integrity findings). This is routine inspection friction, not a warning letter. In February, the Enzene Pune facility received a Pre-Approval Inspection with six procedural observations, zero data-integrity issues—standard compliance noise.

In April 2026, a tax authority demand arrived for ₹333.38 crore disputing FY22–FY23 filings; the company will appeal. Separately, a GST demand of ₹69.65 crore was dropped on appeal (4 May 2026). These are offset legal/tax skirmishes, not material P&L impacts yet.

7. Balance Sheet: The Spreadsheet Speaks

Validation: Assets = Liabilities ✓

The balance sheet expanded 18% to ₹20,873 crore, driven by retained earnings (+15.3%) and a jump in net fixed assets (CWIP and completed assets). Borrowings ticked up from ₹1,381 crore to ₹2,047 crore—still modest. The company holds ₹1,733 crore in cash equivalents (per Screener snapshot), against ₹2,047 crore in debt, netting to a negative ₹314 crore.

Three Snapshots:

Net worth grew ₹1.8 crore per quarter—glacial, underpinned by conservative dividends and reinvestment.

Fixed assets jumped ₹1,163 crore in FY26, a 41% increase. This includes the new Ujjain plant construction and capex for Daman (EU GMP-certified in March 2026) and Baddi (EU GMP-certified in March 2026). Both facilities now have EU approval, a regulatory de-risking. The question mark is whether capex intensity will sustain post-Occlutech close.

Current ratio sits at 2.55 (per Screener snapshot), a comfortable liquidity cushion. But with Occlutech’s ₹1,100 crore cash outlay expected in Q2 FY27, and Ujjain capex ramping, the cash balance will compress. Management flagged ₹1,500 crore annual operating cash accruals, which should cover both, but margin for error narrows.

8. Cash Flow: Sab Number Game Hai

Three years of consistent operating cash generation, ranging ₹1,900–2,000 crore. Investing outflows are steady: capex (₹700–1,000 crore annually) plus acquisition spends. Financing outflows have shrunk (dividend + debt repayment), down from ₹1,145 crore (FY24) to ₹503 crore (FY26).

The pattern shows the company generates enough internally to fund capex without external debt, but Occlutech (~₹1,100 crore) will be a one-time hit to cash. Post-close, cash will fall from the current ₹1,733 crore to ~₹600–700 crore (ballpark). Still above minimum prudential levels, but margin for opportunistic M&A or large one-off capex evaporates.

Wisdom: Cash flow generation is real, but capital allocation is now contested between legacy capex (Ujjain), Occlutech integration, and biosimilar ramps. The company is betting operating leverage (higher EBITDA margin) offsets dilution from new capex and acquisition integration costs.

9. Ratios: Sexy or Stressy?

ROE at 18.9%: The equity base is now ₹13.8 crore (raised by retained earnings). ROE creeping upward (19% from 18% two years ago) but still below 20%—the company is not deploying capital at a return premium to its cost of capital. Occlutech’s acquisition may improve this if the integration scales quickly, but initial years post-close will see integration costs.

ROCE at 21.2%: Higher than ROE due to lower leverage, but still single-digit above the cost of capital (assumed 8–9%). The company is creating value, but margins are slim. Chronic therapy mix shift (semaglutide, anti-diabetes) may improve returns if higher-margin than acute therapies.

P/E at 26.4x: Sits above the company’s 5-year historical average (29.1x, per Screener) and the industry median (31.3x, per peer table). So the stock is cheaper than history or peers, but not on sale. The question is whether FY27–28 earnings growth justifies entry. If semaglutide captures 15–20% market share and grows at 30%+ YoY, incremental earnings could be material. But this is execution risk, not a done deal.

D/E at 0.15: Debt is low, giving the company firepower for Occlutech and future capex without refinancing risk. The stable ratings from Crisil (AA+/Stable) and Fitch reflect this comfort.

10. P&L Breakdown: Show Me the Money

FY26 vs. FY25

Revenue grew ₹1,747 crore (+13.5%). EBITDA grew ₹493 crore (+19.6%), a 28% operating leverage—revenue growth of 13.5% translated to 19.6% EBITDA growth. This reveals margin expansion: revenue climbing at 13.5% dragged EBITDA margin up from 19.4% to 20.4%, a 100 bps shift. Management attributed this to “improving business mix” (read: chronic therapies growing faster, with higher margins) and “cost discipline” (manufacturing efficiency, consolidated distribution, reduced SG&A as a % of sales).

PAT grew only ₹137 crore (+6.3%), slower than EBITDA (+19.6%), because of higher depreciation (₹382 crore vs. ₹357 crore, a 7% jump from capex coming on stream) and higher interest (₹161 crore vs. ₹122 crore, from the new borrowings for capex and Occlutech preparations). Excluding the Q4 non-recurring charges (gratuity liability ₹602.7 crore, real estate impairment ₹747 crore), adjusted FY26 PAT would be ~₹2,650 crore, implying EPS closer to ₹220+. But reported is reported.

Three-Year CAGR (FY24–26)

Revenue: 8.1% (below management’s “13–14% target” and historical 5-yr CAGR of 10.7%).

EBITDA: 15.5% (beat revenue CAGR by 7.4 percentage points, showing margin traction).

PAT: 12.7% (between revenue and EBITDA, dragged down by leverage and depreciation).

The takeaway: the company is still a mid-digit grower on an absolute basis, but margin expansion is now front-and-center. If the domestic chronic ramp accelerates (semaglutide, anti-diabetes) and international growth continues, revenue CAGRs could re-approach 12–15% in FY27–28. But macro (pricing pressure, competition, regulatory) and integration risks (Occlutech, leadership transition) mean delivery is not assured.

11. Peer Comparison

Alkem sits mid-pack by revenue (₹14.7 crore, 4th largest in the sample). But its P/E of 26.4x is below Divi’s (68x) and Torrent (68.8x), suggesting the market prices in different growth expectations.

Alkem’s ROCE (21.2%) is among the highest in the group, exceeded only by Lupin (30.3%). But Lupin’s P/E of 17.9x is a third of Alkem’s 26.4x, implying the market discounts Lupin’s returns or expects faster growth from Alkem. Cipla, despite lower ROCE (15.5%), trades at 29.5x P/E, a comparable multiple.

The spread suggests valuation is not mechanistically tied to ROCE or profitability alone. Narrative—growth visibility, new product upside (semaglutide), geographic expansion (Occlutech), chronic mix shift—matters. Alkem’s story is “execution on semaglutide, integration of Occlutech, steady domestic growth” vs. peers’ stories (Divi’s: CDMO scale-up, Lupin: biosimilar ramp, Sun: US stabilization). The market is pricing in credibility gaps. Alkem’s challenge is to close them.

12. Miscellaneous: Shareholding & Promoters

Promoter Ownership: 51.2% (as of March 2026). The Singh family remains in control. Sarandhar Singh holds 18.75%, Basudeo Narain Singh 7.27%, Mritunjay Kumar Singh 6.42%. Several family members hold smaller stakes, with recent share transfers indicating generational wealth structuring (notes in the shareholding table reference “pending classification changes”). Promoter holding has ticked down from 56.74% (June 2023) to 51.2%, not due to sales but reclassification of family trusts and entities to institutional or public categories.

Institutional Ownership: DIIs (21.4%) and FIIs (10.1%) together hold 31.5%—stable over the past two years, suggesting institutional comfort with the business but not aggressive accumulation. Top DII holders include ICICI Prudential Multi-Asset Fund (3.1%), SBI Large & Midcap Fund (2.4%), HDFC Midcap Fund (4.1%), and Nippon India Trustees (1.9%). These are mid-cap oriented funds, not growth-chasing allocators.

Public Holding: 17.2%, down from 20.85% three years ago. No single individual in the top-10 public shareholders holds >2.9%. This diffusion is typical for mid-cap pharma, but it means no activist investor or large minority stake can override promoter strategy.

Promoter Posture: The Singh family has been lenient with capital deployment (dividends at 25–28% payout ratio, capex-friendly). The CEO transition and Occlutech acquisition suggest promoters are now open to external leadership (search underway) and aggressive M&A, a shift from the conservative posture of prior years. This could be positive (fresh thinking, scaled execution) or a governance shift risk (knowledge loss, integration missteps). The concall emphasized “business will go on because promoters are completely involved,” signalling continuity despite CEO exit. But family-led pharma companies often stumble during leadership transitions if not managed carefully.

13. Corporate Governance: Angels or Devils?

Auditors: BDO India LLP (per concall and filings). Reputable mid-tier firm, not a Big 4, but credible. No adverse audit comments flagged in available filings.

Board Composition: The annual report (FY25) lists a board with promoter directors (including Basudeo Narain Singh, a founder) and independent directors. The Crisil rating report notes “one common independent director on Crisil Ratings and Alkem boards did not participate in rating discussions,” a standard governance protection.

Related-Party Transactions: The data sheet and filings do not highlight unusual related-party concerns. Occlutech is being acquired via Alkem Medtech (a wholly-owned subsidiary), a clean M&A structure.

Pledged Shares: 0% pledged (per Screener snapshot). No collateral stress.

Regulatory Observations:

US FDA Daman facility inspection (April–May 2026) resulted in Form 483 with 7 observations, none data-integrity related. This is routine. Enzene Pune PAI (February 2026) resulted in Form 483 with 6 procedural observations, also routine. Both companies responded with CAPAs (corrective actions) by the deadline.

GST demand of ₹69.65 crore dropped on appeal (May 2026). Tax authority demand of ₹333.38 crore issued (April 2026); company will appeal. These are not unique to Alkem—pharma companies face periodic tax disputes, especially on transfer pricing and R&D tax credits. The company’s tax rate is transitioning from MAT (Minimum Alternate Tax, ~15%) to the new regime, and CFO expects FY27 tax rate to normalise to 27–29%, higher than FY26’s ~18%, but reflecting the cleaner accounting going forward.

CEO Resignation: Dr. Vikas Gupta stepping down 30 June 2026, with a search underway. No accusations of misconduct; the board’s framing suggests planned transition. But the timing—just as Occlutech closes and FY27 execution ramps—introduces management risk. The new CEO will inherit a company mid-integration, with semaglutide scaling, chronic therapy expansion, and capex-heavy capex phase in progress.

Red Flags (Stated as Facts):

Dependence on acute therapeutics (>80% domestic revenue from slower-growing, price-controlled categories) and pricing pressure from generics competition. Biosimilar portfolio is narrow (denosumab, others) and constrained by out-licensing dependencies. International growth is driven by launches offsetting pricing erosion, not volume expansion. Occlutech is a new domain (devices), with different commercial and operational dynamics—integration risk is real.

None of these are disqualifying, but they are material and worth monitoring.

14. Industry Roast & Macro Context

The Indian pharmaceutical industry is a peculiar beast: ~60% of the formulations market is generic (off-patent), driving relentless price competition. Pricing pressure comes from regulators (NPPA price controls), competitors (150+ manufacturers in the top 50 molecules), and distributors (consolidation around hospital chains and e-pharma). Margin compression is structural—unless you own the brand or the process patent, you’re a price taker.

Alkem, despite its #1 position in anti-infectives, faces this squeeze. Acute therapies (antibiotics, NSAIDs, GI agents) are commoditised. The margin migration to chronic therapies (anti-diabetes, cardiology, neurology) is real, but every competitor is pursuing the same shift. Semaglutide in India is a case in point: Alkem launched at ₹350 per injection; competitors (if not already there) will follow within 6–12 months at similar or lower prices. The 11% market share in weeks is impressive, but it’s also a signal of market maturity and price-cutting elasticity.

International markets (US, Europe, RoW) are even harsher. US generics face FDA scrutiny and flooded supply (over 1,000 ANDA approvals annually across the industry). Price erosion on US generics is 5–10% annually. Occlutech’s entry into devices is, in part, a hedge: medical devices have higher barriers (FDA approval, clinical evidence, payer relationships), lower price competition, and higher margins (40–60% vs. 20–30% for pharmaceuticals). But Alkem’s expertise is pharma, not devices. The integration bet is that Alkem’s 12,500-person distribution network can sell Occlutech’s heart devices into Indian hospitals and clinics—a plausible thesis, but not a done deal.

Macro winds:

Pricing Pressure: Across acute and chronic therapies, driven by competition and price controls. NPPA has not announced new price revisions recently, but the risk remains. Semaglutide at ₹350/injection is loss-leading vs. innovator pricing (₹1,800+), signaling volume-for-margin trade-offs.

APIs and Packaging Inflation: Management flagged “increased logistics costs” and “pressure on APIs and packaging materials” due to geopolitics (Russia-Ukraine, China supply chain). CFO cautioned “there will be some impact in first quarter [FY27] and potentially beyond.” This could erode 50–100 bps of EBITDA margin if not offset by price hikes.

FX Volatility: Alkem operates in 80 countries with net positive foreign exchange exposure (US, Europe). Hedging policy is to cover ~80% of exposure, but residual P&L volatility remains. A 5% INR depreciation could add 1–2% to reported revenue growth but compress rupee-denominated margins.

Regulatory Scrutiny: FDA and EMA inspections are increasing (PAI frequency up industry-wide post-COVID). Alkem’s facilities have passed recent audits cleanly, but the observation burden is rising.

Biosimilar Pricing: Global biosimilar pricing is under pressure (EU, US reference pricing). Denosumab launch will enter a crowded market where pricing is 20–30% below originator. This limits upside.

GLP-1 Market Dynamics: Semaglutide’s rapid scale is encouraging but also tells you the market is large and price-elastic. Competitors (Novo Nordisk’s liraglutide generic, tirzepatide when approved) will arrive. Market share will likely settle to single digits per player, and pricing will compress. For Alkem, semaglutide is a multi-quarter growth tail, not a multi-year franchise.

15. EduInvesting Verdict

The Closing Line

Alkem is a balance sheet with nothing to hide and a growth thesis with everything to prove.

The company has executed a decade of steady margin expansion, held strong market positions in domestically-dominated categories, and now pivoted toward chronic therapies and non-pharma diversification. Semaglutide is a near-term catalyst, but it’s also a test case for whether a company built on acute generic strength can scale in fast-moving, price-elastic therapeutic classes. Occlutech is a long bet on geographic arbitrage and devices as a margin hedge, but devices are a different game—FDA-regulated, relationship-intensive, lower volume.

The balance sheet can absorb both bets. The question is whether management—new leadership taking the helm as Occlutech integrates and capex peaks—can execute at scale without distracting from core pharma margin defense. The market is pricing in credibility, trading Alkem at 26x earnings against a historical average of 29x and a peer median of 31x. This assumes execution risk, not home-run upside. That is rational.

The next 18 months will tell whether the pivot to chronic therapies and devices was prescient or a distraction from the core business.